Search
for
Sort by
Research 751–780 of 1000+
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- OA08 Ocrelizumab in pregnancy in a patient with juvenile onset systemic lupus erythematosus
- Recent Formulation Advances of Mangiferin
- Nitric Oxide: Physiological Functions, Delivery, and Biomedical Applications
- Green formulation of spironolactone loaded chitosan coated nano lipid carrier for treatment of acne vulgaris: a randomized double-blind clinical trial
- Beyond the Follicle: A Narrative Review on How Systemic Diseases and Drugs Affect Alopecia
- 4. Bullous/Mucous Membrane
- Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy
- Androgenetic Alopecia in Polycystic Ovary Syndrome: A Cutaneous Marker of Systemic Metabo-inflammatory and Endocrine Dysfunction: A Narrative Review
- Hyperbranched polymer dots enhance hair follicle regeneration via Wnt/β-catenin activation: A drug-free nanozyme-based approach to hair growth therapy
- Synthesis and Structure–Activity Relationships of the First Ferrocenyl-Aryl-Hydantoin Derivatives of the Nonsteroidal Antiandrogen Nilutamide
- Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
- Nature-skin-based multi-responsive controlled-release electroactive scaffolds for integrated melanoma postoperative relapse prevention and wound therapy
- Skin applications of cannabidiol: sources, effects, delivery systems, marketed formulations and safety
- Exploring the role of two polypeptide nanofiber gels derived from RADA16-I self-assembly in accelerating burn wound healing
- Perspective Chapter: Repurposing Natural Products to Target COVID-19 – Molecular Targets and New Avenues for Drug Discovery
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Cutaneous Markers of Disorders Affecting Adult Horses
- Biomaterials Functionalized with MSC Secreted Extracellular Vesicles and Soluble Factors for Tissue Regeneration
- A lipid–polymer hybrid nanoparticle (LPN)-loaded dissolving microneedle patch for promoting hair regrowth by transdermal miR-218 delivery
- Case Report: PTCH1 splice-site mutation and sonidegib treatment in Gorlin-Goltz syndrome: clinical insights from a family case study
- Fluridil, a Rationally Designed Topical Agent for Androgenetic Alopecia
- Role of hair as Evidence in Investigation: A Forensic Approach
- Pharmacological Treatment of Alopecia
- Biocomposite nanofiber matrices to support ECM remodeling by human dermal progenitors and enhanced wound closure
- Targeting ferroptosis in photoaging: mechanisms and therapeutic potential of adipose-derived stem cell exosomes
- Skin aging: mechanisms, evaluation, and rejuvenation
- Premature graying of hair
- Development and Physicochemical Evaluation of a Polyherbal Dual-Action Shampoo for Hair Coloring and Conditioning